S*BIO Expands Pipeline With the Development of a Unique Flt3 -CDK Inhibitor as a Targeted Therapy for Acute Leukemias
SINGAPORE, Nov. 27 /PRNewswire/ -- S*BIO Pte Ltd today announced the
expansion of its proprietary pipeline, with its third development
candidate, SB1317. This is a novel orally-available small molecule compound
targeted for the treatment of acute leukemias.
SB1317 is designed to selectively ...
Low micro-RNA level linked to high gene activity in AML
...tions in two genes in the leukemic cells: NPM1 and flt3
The pattern of microRNA m...l gene.
Furthermore, 26 of the 85 patients had flt3
mutations. These cases also had high levels of a m...igh levels of miR-155 were closely associated with flt3
mutations, they were independent of the mutation (...
Sorafenib Slows Growth of Some Leukemias
...ve the drug to mice with leukemia cells with known flt3
mutations and to leukemia patients with and without the flt3
Sorafenib slowed growth and induced cell death in the flt3
mutant leukemia cells and increased survival of th...
Kidney cancer drug attacks a major type of acute myeloid leukemia
After in vitro tests showed that sorafenib inhibited the growth of flt3
mutant leukemia cell colonies, the research team tested the medication in a...ly results of new therapies under development that more narrowly target the flt3
gene. Andreeff says the drug's ability to hit multiple kinases probably acc...
S*BIO's Oral JAK2 Inhibitor SB1518 Demonstrates Therapeutic Potential for the Treatment of Myeloproliferative and Other Hematological Disorders
... models of hematological malignancies
SB1317, a novel potent inhibitor of flt3
kinase and CDKs 1, 2 and 9,
demonstrated therapeutic potential for the treatment of hematological
is the most common mutated gene in acute myeloid
(AML), and CDK1...
FLT3 in Medical Technology
FLT3 in Biological News
FLT3 in Biological Technology
Kosan Appoints Pamela S. Cohen, M.D., as Chief Medical Officer
...istration filing of Gleevec(TM)
in Ph+ adult acute lymphoblastic leukemia (ALL) and, as global clinical
project leader, successfully brought the first flt3
kinase inhibitor PKC412
(Midostaurin) to Phase 3 in acute myelogenous leukemia (AML). Earlier in
her career at Novartis, Dr. Cohen was responsible for...